Correction: Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET.

Autor: Singh, Simron, Ferone, Diego, Capdevila, Jaume, Chan, Jennifer Ang, de Herder, Wouter W., Halperin, Daniel, Mailman, Josh, Hellström, Lisa, Liedman, Hanna, Svedberg, Agneta, Tiberg, Fredrik
Předmět:
Zdroj: Trials; 6/21/2024, Vol. 25 Issue 1, p1-2, 2p
Abstrakt: This document is a correction notice for an article titled "Methodology of the SORENTO clinical trial: a prospective, randomised, active-controlled phase 3 trial assessing the efficacy and safety of high exposure octreotide subcutaneous depot (CAM2029) in patients with GEP-NET." The correction addresses an error in the original article regarding the administration of CAM2029 compared to octreotide LAR and lanreotide ATG. The corrected statement clarifies that CAM2029 can be self-administered by the patient or carer using a pre-filled pen, while the administration of octreotide LAR and lanreotide ATG requires medical assistance. The correction also provides references for further information on the administration requirements of lanreotide ATG and octreotide LAR. [Extracted from the article]
Databáze: Complementary Index
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje